Aspire Biopharma (ASBP) Holdings received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company remains subject to an extension to evidence compliance with the $2.5M stockholders’ equity requirement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASBP:
- Aspire Biopharma’s Buzz Bomb partners with Blue Shark Beverages
- Aspire Biopharma Raises $2 Million Through Private Financing
- Aspire Biopharma, Microsize partner for sublingual aspirin development
- Aspire files patent application for clopidogrel sublingual powder formulation
- Aspire Biopharma takes delivery of 2M units of BUZZ BOMB